B-cell maturation antigen (BCMA) is a member of the tumor necrosis factor receptor superfamily that plays an important role in regulating B-cell proliferation and survival.1 BCMA is expressed on the cell membrane of normal and malignant plasma cells, but not other normal tissues.2 When bound to its ligands BAFF and APRIL, BCMA delivers pro-survival cell signaling.3
BCMA is central to the survival of multiple myeloma cells.1 BCMA, BAFF, and APRIL are all expressed at significantly higher levels in patients with multiple myeloma than in healthy individuals.1,4 Overexpression leads to upregulation of anti-apoptotic proteins and the survival of multiple myeloma cells.1 Upregulation of BCMA also correlates with disease burden and poor prognosis in multiple myeloma.1
BCMA represents an antigen target of interest for novel multiple myeloma therapies.
Learn more about modalities targeting BCMA:
HLE BiTE® technology.
Watch this video to learn more about the role of BCMA in multiple myeloma and the mechanism of action of BCMA-targeted BiTE® molecules
Search our clinical trials.
Visit our resources section for additional information on potential oncogenic targets.
APRIL: a proliferation inducing ligand; BAFF: B-cell activating factor from the tumor necrosis factor family.
1. Cho S-F, Anderson KC, Tai Y-T. Front Immunol. 2018;9:1821. 2. Seckinger A, Delgado JA, Moser S, et al. Cancer Cell. 2017;31(3):396-410. 3. Coquery CM, Erickson LD. Crit Rev Immunol. 2012;32(4):287-305. 4. Moreaux J, Legouffe E, Jourdan E, et al. Blood. 2004;103(8):3148-3157.